George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

17 Oct 2019 14:20

RNS Number : 2768Q
Mereo BioPharma Group plc
17 October 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Mereo Biopharma Group PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:No trading in the stock - voting control interest over stock transferred to new manager

X

3. Details of person subject to the notification obligationiv

Name

Woodford Investment Management Ltd

City and country of registered office (if applicable)

Oxford, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

15/10/2019

6. Date on which issuer notified (DD/MM/YYYY):

17/10/2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

8.00%

8.00%

97,959,622

Position of previous notification (if

applicable)

27.56%

27.56%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BZ4G2K23

7,845,873

8.00%

SUBTOTAL 8. A

7,845,873

8.00%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Woodford Investment Management Ltd

8.00

0.00

8.00

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Oxford

Date of completion

17/10/2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLGGGMGUUPBGWM
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.